Rivera-Rivera Stephanie, Morales-Malave Arelis N, Choudens Raul Rios-De, Otero-Dominguez Yomayra, Marin-Garcia Gerald L, Rodriguez-Cintron William
Veterans Affairs Caribbean Healthcare System, San Juan, Puerto Rico.
Fed Pract. 2025 Apr;42(4):171-175. doi: 10.12788/fp.0575. Epub 2025 Apr 15.
Pulmonary embolism is a common cause of morbidity and mortality in the United States. A nonspecific clinical presentation makes it challenging to diagnose, and management varies significantly depending on a risk-benefit assessment, the patient's current clinical status, and institutional practices.
Multidisciplinary appraisal led to differing use of tissue plasminogen activator (tPA) infusion for 2 patients at intermediate-risk for pulmonary embolism. Both cases demonstrated favorable outcomes and improved right ventricular function after treatment. One patient underwent systemic tPA infusion and demonstrated resolution of pulmonary hypertension and symptoms after 24 hours. A second patient received localized tPA infusion for 24 hours and had a marked decrease in clot burden and pulmonary artery pressure gradient.
These cases illustrate the variety and complexity of management of patients with intermediate-risk pulmonary embolism and highlight the role institutional pulmonary embolism response teams may have in these scenarios.
在美国,肺栓塞是发病和死亡的常见原因。其临床表现不具特异性,诊断颇具挑战性,治疗方案会因风险效益评估、患者当前临床状况及机构惯例而有显著差异。
多学科评估导致两名肺栓塞中危患者使用组织型纤溶酶原激活剂(tPA)输注的方式不同。两例治疗后均显示出良好预后且右心室功能改善。一名患者接受了全身性tPA输注,24小时后肺动脉高压及症状得到缓解。另一名患者接受了24小时局部tPA输注,血栓负荷及肺动脉压力梯度显著降低。
这些病例说明了中危肺栓塞患者治疗的多样性和复杂性,并凸显了机构肺栓塞应对团队在这些情况下可能发挥的作用。